Kanwal Raghav
YOU?
Author Swipe
View article: Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response
Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response Open
Escalated doses of radiotherapy associate with improved local control and overall survival (OS) in intrahepatic cholangiocarcinoma (iCCA), but personalization remains limited because conventional size-based CT criteria correlate poorly wit…
View article: Data from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors
Data from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors Open
Purpose:Intratumoral injection of Clostridium novyi-nontoxic (C. novyi-NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study in…
View article: Supplementary Figure S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors
Supplementary Figure S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors Open
Supplementary Figure S1. Systemic tumor antigen specific T-cell responses.
View article: Supplementary Figure S2 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors
Supplementary Figure S2 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors Open
Supplementary Figure S2. Lymphocyte infiltration in tumor biopsies.
View article: Supplementary Table S3 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors
Supplementary Table S3 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors Open
Supplementary Table S3. Patient-Level Data on MSI Status, TMB, Injection Site, Tumor Size, and Prior IO Exposure.
View article: Supplementary Table S2 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors
Supplementary Table S2 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors Open
Supplementary Table S2. Study Representativeness Table.
View article: Supplementary Table S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors
Supplementary Table S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors Open
Supplementary Table S1. Planned dose levels of Clostridium novyi-NT given intratumorally in combination with the PD-1 inhibitor, pembrolizumab at 200mg intravenously every 3 weeks (cycle = 21 days).
View article: Supplementary File S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors
Supplementary File S1 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors Open
Supplementary File S1. Study protocol.
View article: Supplementary Table S4 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors
Supplementary Table S4 from Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i>-NT in Patients with Advanced Solid Tumors Open
Supplementary Table S4. Anti-tumor efficacy in injected lesion(s) and best overall response per RECISTv1.1 among enrolled participants.
View article: Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial Open
CEACAM5, a cell surface protein, is overexpressed in colorectal cancer (CRC). Precemtabart tocentecan (Precem-TcT, previously M9140) is an anti-CEACAM5 antibody–drug conjugate with the topoisomerase 1 inhibitor exatecan as payload. Precem-…
View article: Data from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Data from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Purpose:A combination of two HER2-directed antibodies, pertuzumab and trastuzumab (P + T), has antitumor activity in HER2-positive colorectal cancer. Although liquid biopsies are increasingly being used in clinical oncology, the associatio…
View article: Figure S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Figure S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Figure 1
View article: Table S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 2
View article: Figure S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Figure S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Figure 2
View article: Table S3 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S3 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 3
View article: Table S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 1
View article: Table S4 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S4 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Supplementary Table 4
View article: Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i> -NT in Patients with Advanced Solid Tumors
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of <i>Clostridium novyi</i> -NT in Patients with Advanced Solid Tumors Open
Purpose: Intratumoral injection of Clostridium novyi-nontoxic (C. novyi-NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study investigated th…
View article: Consensus guideline for the management of peritoneal mesothelioma
Consensus guideline for the management of peritoneal mesothelioma Open
The treatment of peritoneal mesothelioma (PeM) poses significant challenges because of its rare incidence, heterogeneity, and limited clinical evidence. This commentary describes results from a national consensus aimed at addressing the ma…
View article: ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial Open
Purpose: A combination of two HER2-directed antibodies, pertuzumab and trastuzumab (P + T), has antitumor activity in HER2-positive colorectal cancer. Although liquid biopsies are increasingly being used in clinical oncology, the associati…
View article: BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy Open
View article: Supplementary Table S3 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Table S3 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Supplementary Table S3: 70 gene ctDNA panel
View article: Supplementary Table S2 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Table S2 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Supplementary Table S2: Co-occuring circulating mutations in AA
View article: Data from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Data from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Purpose:Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal adeno…
View article: Supplementary Table S1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Table S1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Supplementary Table 1: Actionable mutations noted in ctDNA of AA patients
View article: Supplementary Data 1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Data 1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Appendiceal Adenocarcinoma Circulating Mutational Profiles
View article: Supplementary Figures 1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma
Supplementary Figures 1 from The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Supplementary Figures
View article: Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations Open
View article: Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01 Open
View article: The Landscape of ctDNA in Appendiceal Adenocarcinoma
The Landscape of ctDNA in Appendiceal Adenocarcinoma Open
Purpose: Appendiceal adenocarcinoma is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of appendiceal aden…